Literature DB >> 24644003

Longitudinal changes in BMD and fracture risk in orthotopic liver transplant recipients not using bone-modifying treatment.

Charlotte G Krol1, Olaf M Dekkers, Herman M Kroon, Ton J Rabelink, Bart van Hoek, Neveen At Hamdy.   

Abstract

Osteoporosis is prevalent in end-stage liver disease, but data on long-term changes in bone mineral density (BMD) and related fracture incidence after orthotopic liver transplantation (OLT) are scarce. We evaluated BMD changes up to 5 years in consecutive recipients of a successful OLT at the Leiden University Medical Centre between 2000 and 2011, in whom sequential BMD data were available. Spinal radiographs were available at time of screening and at 6 and 12 months post-OLT and were assessed for vertebral fractures by two independent observers using Genant's semiquantitative method. Patients were excluded from the study when started on bisphosphonates. A total of 201 patients (71% men), median age 53 years (range, 18-70 years) were included in the study. Most common liver pathology was viral (27%) or alcoholic liver disease (25%). All patients received prednisone for at least 6 months after transplantation and the majority received either tacrolimus or cyclosporine for immunosuppression. At time of screening for OLT, osteoporosis and osteopenia were found in 18% and 36% of patients at the lumbar spine (LS), respectively, and in 9% and 42% at the femoral neck (FN), respectively. T-scores declined significantly at both sites 6 months after OLT, but increased thereafter at the LS, reaching pretransplantation values at 2 years and remaining stable thereafter. FN T-scores remained consistently lower than pretransplantation values. The prevalence of vertebral fractures increased from 56% at screening to 71% at 1 year after OLT, with a fracture incidence of 34%. BMD changes did not predict fracture risk. Osteoporosis, osteopenia, and vertebral fractures are prevalent in patients with end-stage liver disease. An overall decline in BMD is observed within the first 6 months after OLT, with subsequent recovery to pretransplantation values at the LS, but not at the FN. Vertebral fracture risk is high after OLT regardless of changes in BMD.
© 2014 American Society for Bone and Mineral Research.

Entities:  

Keywords:  DXA; EPIDEMIOLOGY; FRACTURE RISK; INCIDENCE OSTEOPOROSIS; OSTEOPOROSIS; VERTEBRAL FRACTURES

Mesh:

Substances:

Year:  2014        PMID: 24644003     DOI: 10.1002/jbmr.2214

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  5 in total

1.  Complications and safety of the transplanted organ after upper extremity surgery in patients receiving immunosuppressant therapy after solid organ transplantation.

Authors:  Seonjeong Lee; Jae Kwang Kim; Sohyun Oh; Young Ho Shin
Journal:  Int Orthop       Date:  2021-07-02       Impact factor: 3.075

2.  Factors associated with 1,25-dihydroxyvitamin D3 concentrations in liver transplant recipients: a prospective observational longitudinal study.

Authors:  Agnieszka Prytuła; Johan Vande Walle; Hans Van Vlierberghe; Jean-Marc Kaufman; Tom Fiers; Jo Dehoorne; Ann Raes
Journal:  Endocrine       Date:  2015-10-03       Impact factor: 3.633

Review 3.  Physical Function, Physical Activity, and Quality of Life After Liver Transplantation.

Authors:  Michael A Dunn; Shari S Rogal; Andres Duarte-Rojo; Jennifer C Lai
Journal:  Liver Transpl       Date:  2020-05       Impact factor: 5.799

Review 4.  Interventions for preventing bone disease in kidney transplant recipients.

Authors:  Suetonia C Palmer; Edmund Ym Chung; David O McGregor; Friederike Bachmann; Giovanni Fm Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2019-10-22

5.  Bone metabolism dynamics in the early post-transplant period following kidney and liver transplantation.

Authors:  Peter W Schreiber; Heike A Bischoff-Ferrari; Katia Boggian; Marco Bonani; Christian van Delden; Natalia Enriquez; Thomas Fehr; Christian Garzoni; Hans H Hirsch; Cédric Hirzel; Oriol Manuel; Pascal Meylan; Lanja Saleh; Maja Weisser; Nicolas J Mueller
Journal:  PLoS One       Date:  2018-01-16       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.